SpringWorks Therapeutics Inc (SWTX)
36.30
-1.14
(-3.04%)
USD |
NASDAQ |
Nov 21, 16:00
36.60
+0.30
(+0.83%)
Pre-Market: 08:59
SpringWorks Therapeutics Enterprise Value: 2.324B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 2.324B |
| November 20, 2024 | 2.408B |
| November 19, 2024 | 2.445B |
| November 18, 2024 | 2.194B |
| November 15, 2024 | 2.335B |
| November 14, 2024 | 2.342B |
| November 13, 2024 | 2.205B |
| November 12, 2024 | 2.086B |
| November 11, 2024 | 2.117B |
| November 08, 2024 | 2.152B |
| November 07, 2024 | 2.085B |
| November 06, 2024 | 2.078B |
| November 05, 2024 | 1.973B |
| November 04, 2024 | 1.923B |
| November 01, 2024 | 1.900B |
| October 31, 2024 | 1.863B |
| October 30, 2024 | 1.889B |
| October 29, 2024 | 1.863B |
| October 28, 2024 | 1.845B |
| October 25, 2024 | 1.802B |
| October 24, 2024 | 1.787B |
| October 23, 2024 | 1.750B |
| October 22, 2024 | 1.838B |
| October 21, 2024 | 1.890B |
| October 18, 2024 | 1.926B |
| Date | Value |
|---|---|
| October 17, 2024 | 1.911B |
| October 16, 2024 | 1.862B |
| October 15, 2024 | 1.891B |
| October 14, 2024 | 1.887B |
| October 11, 2024 | 1.903B |
| October 10, 2024 | 1.879B |
| October 09, 2024 | 1.928B |
| October 08, 2024 | 2.033B |
| October 07, 2024 | 2.022B |
| October 04, 2024 | 2.050B |
| October 03, 2024 | 1.989B |
| October 02, 2024 | 2.064B |
| October 01, 2024 | 2.018B |
| September 30, 2024 | 2.005B |
| September 27, 2024 | 2.014B |
| September 26, 2024 | 2.014B |
| September 25, 2024 | 2.031B |
| September 24, 2024 | 2.004B |
| September 23, 2024 | 2.058B |
| September 20, 2024 | 2.170B |
| September 19, 2024 | 2.242B |
| September 18, 2024 | 2.259B |
| September 17, 2024 | 2.247B |
| September 16, 2024 | 2.257B |
| September 13, 2024 | 2.395B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
494.79M
Minimum
Nov 25 2019
4.075B
Maximum
Feb 24 2021
1.989B
Average
1.873B
Median
Oct 05 2020
Enterprise Value Benchmarks
| Ocugen Inc | 226.64M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -53.53M |
| Revenue (Quarterly) | 49.30M |
| Total Expenses (Quarterly) | 107.24M |
| EPS Diluted (Quarterly) | -0.72 |
| Gross Profit Margin (Quarterly) | 93.22% |
| Profit Margin (Quarterly) | -108.6% |
| Earnings Yield | -10.72% |
| Normalized Earnings Yield | -10.72 |